Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
49.6M
-
Number of holders
-
82
-
Total 13F shares, excl. options
-
21.2M
-
Shares change
-
+3.23M
-
Total reported value, excl. options
-
$120M
-
Value change
-
+$12.5M
-
Put/Call ratio
-
0.62
-
Number of buys
-
62
-
Number of sells
-
-22
-
Price
-
$5.65
Significant Holders of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) as of Q1 2025
104 filings reported holding CADL - Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q1 2025.
Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) has 82 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.2M shares
of 49.6M outstanding shares and own 42.7% of the company stock.
Largest 10 shareholders include FMR LLC (7.09M shares), BAKER BROS. ADVISORS LP (2.44M shares), ACORN CAPITAL ADVISORS, LLC (2.15M shares), BlackRock, Inc. (1.76M shares), VANGUARD GROUP INC (1.74M shares), Portolan Capital Management, LLC (881K shares), Halter Ferguson Financial Inc. (693K shares), GEODE CAPITAL MANAGEMENT, LLC (687K shares), STATE STREET CORP (563K shares), and Sands Capital Ventures, LLC (406K shares).
This table shows the top 82 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.